Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
As GLP-1 medications become more widespread, so does the challenge of weight regain when patients stop — and the emotional fallout that follows. Clinicians are being urged to screen for depression, use patient-centered language, and reframe regain as a manageable clinical challenge rather than a personal failure. The goal: keep patients engaged in their health journey even without the medication.
GLP-1 receptor agonists have reshaped obesity treatment, but fewer than 1 in 4 patients remain on therapy after 12 months — and when they stop, weight regain is common. That regain can trigger shame, sadness, and disengagement from care, making mental health support a critical but often overlooked part of the clinical picture. Experts recommend that physicians start conversations about realistic expectations early, before patients ever discontinue, so they understand that lifestyle strategies remain central to obesity management regardless of medication status.
When weight does return, primary care physicians should screen for all nine DSM depression symptoms, assess functionality and suicidality, and use nonjudgmental, open-ended language. Framing regain as a treatable clinical challenge — not a moral failing — can reduce stigma and keep patients motivated. Behavioral health referrals, including brief CBT or behavioral activation, should be normalized as standard team care.
Key Takeaways:
Why it matters: With millions of Americans cycling on and off GLP-1 medications due to cost and access issues, clinicians need practical tools to address the psychological toll of weight regain — or risk losing patients to shame-driven disengagement from care altogether.
